Carrie Brownstein's most recent trade in Shattuck Labs Inc was a trade of 27,700 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 21, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Shattuck Labs Inc | Carrie Brownstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 27,700 | 27,700 | - | - | Stock Option (Right to Buy) | |
Shattuck Labs Inc | Carrie Brownstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 40,258 | 40,258 | - | - | Stock Option (Right to Buy) | |
Zentalis Pharmaceuticals Inc | Carrie Brownstein | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 23,687 | 23,687 | - | - | Stock Option (Right to Buy) | |
Zentalis Pharmaceuticals Inc | Carrie Brownstein | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 16,313 | 116,313 | - | 0 | Common Stock | |
Shattuck Labs Inc | Carrie Brownstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 10,467 | 10,467 | - | - | Stock Option (Right to Buy) |